---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-015303"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T09:03:29.938231+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences President & CSO Kirk resigns, enters $41K/mo advisor deal

## Summary
- Christopher Kirk resigned as President and CSO effective April 21, 2023, remains on board.
- Advisor agreement runs April 22 to Dec 31, 2023 at $41,050/month plus COBRA premiums.
- Kirk declines cash and equity compensation under Non-Employee Director Compensation Policy during term.

## SEC filing metadata
- accession: 0000950170-23-015303
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023015303/0000950170-23-015303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023015303/kzr-20230421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-015303
- JSON: https://secwatch.observer/filing/0000950170-23-015303.json
- Plain text: https://secwatch.observer/filing/0000950170-23-015303.txt

## Key facts
- Executive change
  Christopher Kirk resigned as President and Chief Scientific Officer at Kezar Life Sciences, Inc..
  - Action: resigned
  - Role: President and Chief Scientific Officer
  source text: On April 21, 2023, as previously announced, Christopher Kirk, Ph.D. resigned from his role as President and Chief Scientific Officer of Kezar Life Sciences, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023015303/0000950170-23-015303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.